Free Trial
NASDAQ:FEMY

Femasys 3/28/2024 Earnings Report

Femasys logo
$1.16 -0.01 (-0.85%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.17 +0.01 (+0.86%)
As of 05/2/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Femasys EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.19
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Femasys Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.30 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

Femasys Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Femasys' next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Femasys Earnings Headlines

Femasys reports FY24 EPS (85c), consensus (81c)
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Femasys enters partnership with CNY Fertility
Femasys price target raised to $15 from $12 at H.C. Wainwright
See More Femasys Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email.

About Femasys

Femasys (NASDAQ:FEMY), a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

View Femasys Profile

More Earnings Resources from MarketBeat